China’s Contribution to Implementing ICH E17 MRCT Guidelines

Introduction

The International Council for Harmonisation (ICH) E17 guideline on multi-regional clinical trials (MRCTs) has reshaped global drug development, encouraging efficient, harmonized trials that support simultaneous submissions across regions. China, under the National Medical Products Administration (NMPA), has emerged as a pivotal player in implementing ICH E17, leveraging its vast patient population, strengthened regulatory framework, and growing clinical research capacity. For sponsors, China’s participation ensures diversity in trial populations and global acceptance of Chinese data. This article explores China’s role in ICH E17 MRCT implementation, analyzing regulatory reforms, operational challenges, and best practices for sponsors integrating Chinese sites into multinational programs.

Background and Regulatory Framework

ICH E17 Overview

ICH E17 provides principles for planning and designing MRCTs, including sample size allocation, regional subgroup analyses, and regulatory coordination. Its goal is to streamline drug development, avoid duplicative bridging studies, and ensure data acceptability across multiple agencies.

NMPA’s Adoption of ICH E17

The NMPA formally adopted ICH E17 in 2019, requiring sponsors to justify Chinese patient enrollment, design regionally representative protocols, and ensure statistical power for subgroup analyses. This adoption signaled China’s full alignment with international MRCT practices.

Case Example: Diabetes MRCT

A diabetes MRCT included 1,200 Chinese patients across 40 sites. By adhering to ICH E17 and NMPA guidance, the sponsor integrated Chinese data into global submissions accepted simultaneously by the FDA, EMA, and NMPA, avoiding a bridging study.

Core Clinical Trial Insights

China’s Strategic Role in MRCTs

China offers unparalleled recruitment capacity, particularly in oncology, diabetes, and cardiovascular diseases. Including Chinese patients enhances trial diversity and ensures therapies are representative of Asian populations, strengthening global acceptance of data.

Regulatory Engagement Under E17

Sponsors must engage the NMPA early to confirm patient enrollment targets, regional subgroup strategies, and data localization compliance. Mid-trial consultations help align ongoing MRCTs with evolving NMPA requirements, minimizing delays.

Statistical and Operational Considerations

ICH E17 emphasizes adequate statistical power for regional subgroups. For China, this requires sufficient sample sizes to allow meaningful analysis of Chinese data. Sponsors must also ensure consistency in CRF translation, CDISC compliance, and bilingual data integration.

Data Localization and Harmonization

China’s data localization laws require that trial data be stored domestically, creating challenges for multinational integration. Sponsors must establish local IT systems while ensuring harmonization with global databases for simultaneous submissions.

Role of CROs in E17 Implementation

CROs with expertise in Chinese regulatory requirements support MRCT planning, site initiation, and monitoring. They bridge operational gaps between global protocols and local expectations, ensuring data quality and inspection readiness.

Inspection Trends in MRCTs

The NMPA inspects MRCT sites for adherence to GCP, protocol compliance, and data integrity. Sponsors must prepare Chinese sites for dual inspections from both the NMPA and global regulators (FDA, EMA), ensuring consistency in documentation and SOPs.

Best Practices & Preventive Measures

Sponsors should:
Engage with the NMPA early for MRCT protocol review
Allocate sufficient Chinese patient enrollment for subgroup analysis
Harmonize CRFs and TMFs with global CDISC standards
Prepare Chinese sites for multinational inspections
Partner with CROs with strong China expertise
Incorporate bilingual training for investigators and site staff
These practices ensure successful implementation of ICH E17 in China.

Scientific & Regulatory Evidence

ICH E17 principles are supported by ICH E6(R2) GCP, WHO MRCT guidance, and NMPA technical documents. Comparative evidence shows that inclusion of Chinese patients enhances generalizability of trial results and accelerates global approvals by eliminating bridging study requirements.

Special Considerations

Rare disease MRCTs in China require special planning due to small patient populations and HGRAC oversight of genetic data. Pediatric trials also demand ethical safeguards, including culturally adapted consent forms for families.

When Sponsors Should Seek Regulatory Advice

Sponsors should consult the NMPA at the MRCT design stage to confirm patient allocation, data integration strategies, and compliance with data localization. Regulatory advice ensures trial designs meet both Chinese and global expectations.

Case Studies

Case Study 1: Oncology MRCT Alignment

A multinational oncology sponsor conducted an MRCT with 500 Chinese patients. By aligning with ICH E17 and NMPA requirements, the sponsor achieved simultaneous approvals in China, the U.S., and the EU, accelerating global patient access.

Case Study 2: Rare Disease MRCT Strategy

A rare disease MRCT in China faced recruitment challenges. The sponsor collaborated with patient advocacy groups and used registry-based screening, achieving sufficient enrollment to support NMPA and FDA approvals without bridging studies.

FAQs

1. What is the ICH E17 guideline?

ICH E17 provides principles for designing MRCTs to ensure global data acceptance and avoid duplicative bridging studies.

2. How has China adopted ICH E17?

The NMPA formally adopted ICH E17 in 2019, requiring sponsors to justify Chinese patient enrollment and regional representativeness.

3. Why is China important for MRCTs?

China provides large patient populations, enhances diversity, and ensures Asian data are represented in global submissions.

4. What are the main challenges of E17 implementation in China?

Challenges include data localization, bilingual documentation, site readiness, and ensuring adequate statistical power for Chinese subgroups.

5. How can sponsors align with NMPA expectations?

Through early consultations, sufficient patient allocation, CRO partnerships, and harmonized data management systems.

6. Can Chinese MRCT data be used in FDA/EMA submissions?

Yes, if trials comply with ICH E17 and global standards, Chinese data are accepted in multinational submissions without additional bridging studies.

Conclusion & Call-to-Action

China’s role in implementing ICH E17 MRCT guidelines has strengthened its position as a key player in global drug development. By adopting international standards and enhancing regulatory oversight, the NMPA ensures that Chinese trial data are globally accepted. Sponsors must embrace best practices in regulatory engagement, site readiness, and data harmonization to successfully integrate China into MRCTs. Organizations planning multinational trials should prioritize China as a strategic region to accelerate approvals and expand patient access worldwide.

When Bridging Studies Are Needed in Chinese Clinical Trials

Introduction

Bridging studies play a critical role in global clinical development by determining whether foreign clinical data can be applied to the Chinese population. For decades, sponsors faced mandatory bridging studies in China, often delaying patient access to innovative therapies. However, regulatory reforms under the National Medical Products Administration (NMPA) and China’s adoption of International Council for Harmonisation (ICH) E5 and E17 guidelines have reshaped the requirements for bridging studies. Today, bridging studies are required selectively, primarily when ethnic sensitivity or regional factors affect drug response, safety, or pharmacokinetics. This article provides a regulatory perspective on bridging studies in China, explaining when they are required, how they are designed, and what strategies sponsors can adopt to streamline global development plans.

Background and Regulatory Framework

Historical Requirement for Bridging Studies

Before 2015, China’s regulatory authority (CFDA) often required foreign-developed drugs to undergo local bridging studies regardless of existing global data. This created significant delays, sometimes adding years to drug approval timelines. The intent was to ensure safety and efficacy in the Chinese population, but the approach lacked flexibility.

Reforms Under the NMPA

Since 2015, the NMPA has adopted a risk-based approach, guided by ICH E5 (Ethnic Factors in the Acceptability of Foreign Clinical Data). Bridging studies are now required only when differences in genetics, diet, environment, or medical practice may affect drug response. The NMPA also accepts multinational trial data if Chinese patients are adequately represented, reducing the need for separate bridging studies.

Case Example: Oncology Drug Bridging

A U.S.-developed oncology drug once required a full bridging study in China. After reforms, the NMPA accepted multinational Phase III trial data that included Chinese patients, eliminating the need for a separate study. This reduced the drug lag by nearly two years.

Core Clinical Trial Insights

When Are Bridging Studies Required?

Bridging studies are required if:
Genetic differences affect pharmacokinetics or pharmacodynamics (e.g., CYP450 metabolism variations).
Environmental or dietary factors influence drug response.
Local medical practices differ significantly from those in foreign studies.
There is limited representation of Chinese patients in global trials.
Bioequivalence data for generics must be confirmed in Chinese subjects.
These criteria ensure drug safety and efficacy for the Chinese population.

Study Designs for Bridging

Bridging studies may take several forms:
Phase I PK/PD studies in healthy Chinese volunteers.
Phase II or III efficacy studies in Chinese patients for specific indications.
Bioequivalence (BE) studies for generic drugs.
Subpopulation analyses in multinational trials.
Study design depends on the type of drug, therapeutic area, and availability of global data.

Ethnic Sensitivity and Pharmacogenomics

Ethnic sensitivity is a central factor in bridging decisions. Differences in drug metabolism, such as higher prevalence of CYP2C19 poor metabolizers among Chinese patients, may warrant bridging studies. The NMPA requires pharmacogenomic data to assess whether foreign clinical data can be extrapolated.

Acceptance of Multinational Trial Data

The NMPA increasingly accepts multinational trial data if Chinese patients are adequately included. This aligns with ICH E17 guidelines on multinational clinical trials (MRCTs). For example, including 300–500 Chinese patients in a global Phase III trial may eliminate the need for separate bridging.

Challenges in Bridging Study Implementation

Sponsors must navigate ethical approval processes, site readiness, and patient recruitment. Bridging studies can be delayed by competition at Tier-1 hospitals and limited infrastructure in Tier-2 hospitals. CRO partnerships are essential for smooth execution and compliance.

Therapeutic Area Variability

Oncology, cardiovascular, and central nervous system drugs often face bridging requirements due to variability in response. In contrast, bridging studies are less common for antibiotics or drugs with well-characterized mechanisms and low variability.

Best Practices & Preventive Measures

Sponsors should design global trials to include adequate Chinese representation, reducing the need for bridging. Early engagement with the NMPA helps clarify bridging expectations and avoid delays. Using PK/PD modeling and simulation can also support waivers by demonstrating equivalence across populations. CRO partnerships enhance trial execution and regulatory compliance.

Scientific & Regulatory Evidence

NMPA guidance is based on ICH E5 and E17, WHO GCP, and domestic regulations. Comparative evidence with FDA and EMA demonstrates increasing convergence, though China emphasizes ethnic sensitivity more strongly. The 2019 Drug Administration Law further supports flexible acceptance of multinational data while ensuring safety and efficacy in Chinese patients.

Special Considerations

Bridging studies are especially important in rare diseases, where Chinese patient representation in global trials is limited. Pediatric bridging may also be required due to age-related differences in metabolism and treatment practices. Sponsors must also comply with Human Genetic Resources Administration of China (HGRAC) regulations when genetic samples are involved.

When Sponsors Should Seek Regulatory Advice

Sponsors should consult the NMPA early during global development planning to determine whether bridging studies will be required. Pre-IND consultations can clarify expectations for ethnic sensitivity assessments, study design, and patient enrollment. Regulatory advice is also critical when planning MRCTs to ensure adequate Chinese representation.

Case Studies

Case Study 1: Cardiovascular Drug Bridging Study

A cardiovascular drug developed in Europe faced a bridging requirement in China due to genetic differences in metabolism. A Phase I PK study in healthy Chinese volunteers demonstrated comparable exposure, allowing the drug to proceed without a full Phase III trial, reducing development timelines.

Case Study 2: Rare Disease Trial Bridging Waiver

A rare disease therapy conducted a multinational Phase III trial with 500 Chinese patients included. The NMPA waived the bridging requirement, accepting global data for NDA submission. This expedited approval by over one year, demonstrating the value of early Chinese patient inclusion.

FAQs

1. What are bridging studies in China?

They are studies that assess whether foreign clinical data can be applied to Chinese patients, considering genetic, environmental, and cultural factors.

2. Are bridging studies always required in China?

No. Since NMPA reforms, bridging studies are required only when ethnic or environmental differences may affect drug safety or efficacy.

3. How can sponsors avoid bridging studies?

By including adequate numbers of Chinese patients in multinational trials and providing pharmacogenomic data to demonstrate equivalence.

4. What types of drugs often require bridging studies?

Oncology, cardiovascular, and CNS drugs often require bridging due to genetic variability in response.

5. How do NMPA bridging requirements compare globally?

They are aligned with ICH E5/E17, similar to FDA and EMA expectations, but with stronger emphasis on ethnic sensitivity.

6. What role do CROs play in bridging studies?

CROs support site selection, ethics approvals, and patient recruitment, ensuring bridging studies are executed efficiently and compliantly.

Conclusion & Call-to-Action

Bridging studies in China have evolved from rigid requirements under the CFDA to a flexible, risk-based framework under the NMPA. Today, sponsors must assess ethnic sensitivity, patient representation, and therapeutic area factors to determine whether bridging is necessary. By including Chinese patients in global trials, engaging the NMPA early, and leveraging CRO expertise, sponsors can streamline development and reduce delays. Organizations planning global submissions should integrate bridging strategies into feasibility planning to ensure compliance and accelerate patient access in China.

The Transformation of Clinical Trials in China: From CFDA to NMPA

Introduction

The transition from the China Food and Drug Administration (CFDA) to the National Medical Products Administration (NMPA) in 2018 marked a pivotal moment in the modernization of China’s clinical trial and regulatory landscape. For decades, sponsors faced long timelines, unclear requirements, and inconsistent data acceptance under the CFDA. With the NMPA, China signaled its commitment to global harmonization, efficiency, and patient safety. The reforms have shortened trial initiation timelines, expanded site accreditation, and strengthened Good Clinical Practice (GCP) enforcement. These changes not only increased China’s attractiveness for multinational clinical trials but also improved domestic innovation capacity. This article explores the impact of the CFDA-to-NMPA transition on clinical trials, detailing regulatory reforms, operational improvements, and strategic implications for sponsors.

Background and Regulatory Framework

CFDA’s Limitations

Under the CFDA, sponsors often waited two to three years for trial approvals. Limited regulatory resources and a lack of harmonization with ICH guidelines led to delays and inefficiencies. Bridging studies were frequently required, further delaying patient access to innovative therapies.

Creation of the NMPA

In 2018, the CFDA was restructured into the NMPA under the State Administration for Market Regulation. This move centralized oversight of drugs, devices, and cosmetics while modernizing regulatory processes. The NMPA gained expanded authority, increased staffing, and a mandate to align with international best practices.

Case Example: Bridging Study Reform

Previously, foreign drugs often required separate Chinese bridging studies before approval. Under the NMPA, acceptance of multinational trial data has become more common, eliminating redundancies and reducing drug lag for oncology and rare disease therapies.

Core Clinical Trial Insights

IND and CTA Approvals

The introduction of the 60-day “silent approval” system under the NMPA revolutionized trial initiation timelines. While CFDA approvals could take years, the NMPA now aligns with global standards, similar to FDA and EMA review timelines. This has significantly improved China’s attractiveness for global sponsors.

Ethics Review and Oversight

The NMPA strengthened the role of ethics committees, requiring standardized processes and piloting centralized ethics reviews for multicenter trials. This addressed long-standing inconsistencies in ethical oversight under the CFDA.

Data Integrity and Inspections

The NMPA implemented risk-based GCP inspections to address historical concerns about data reliability. In 2015, a major audit revealed widespread issues, but subsequent reforms have improved data credibility, aligning China’s standards with ICH E6(R2).

Site Accreditation Reforms

One of the most significant changes was the move from a restrictive site approval model to a streamlined site filing system. This reform expanded the number of eligible hospitals and reduced trial initiation bottlenecks, addressing one of the major limitations of the CFDA era.

Accelerated Approval Pathways

The NMPA introduced Breakthrough Therapy, Priority Review, and Conditional Approval mechanisms, particularly benefiting oncology and rare disease drugs. These reforms mirror FDA and EMA expedited pathways, ensuring earlier access for Chinese patients.

Impact on CROs and Sponsors

CROs and sponsors had to adapt rapidly to new compliance requirements, inspection standards, and operational timelines. While challenging, these reforms positioned China as a competitive environment for multinational clinical development.

Best Practices & Preventive Measures

Sponsors should integrate China into global clinical development plans earlier, leveraging NMPA’s acceptance of multinational data. Early engagement with regulators through pre-IND consultations helps clarify expectations. CRO partnerships are critical for ensuring site readiness, ethics compliance, and inspection preparedness. Establishing harmonized SOPs across global and Chinese sites prevents compliance gaps.

Scientific & Regulatory Evidence

The NMPA reforms reflect alignment with ICH E6(R2) GCP, ICH E17 MRCT guidelines, and WHO GCP. Comparative evidence with FDA and EMA expedited review pathways demonstrates convergence in regulatory practices. The 2019 Drug Administration Law further reinforced pharmacovigilance and post-market safety, elevating China’s system to global standards.

Special Considerations

Despite progress, challenges remain. Ethics review fragmentation continues in some regions, and site capacity disparities between Tier-1 and Tier-2 hospitals persist. Sponsors must consider China’s data localization laws, which require domestic storage of patient data and genetic materials, impacting multinational data integration.

When Sponsors Should Seek Regulatory Advice

Sponsors should consult the NMPA when planning IND submissions, adaptive trial designs, or trials involving genetic data subject to Human Genetic Resources Administration of China (HGRAC) oversight. Pre-IND and mid-trial consultations help clarify expectations, reducing delays and compliance risks.

Case Studies

Case Study 1: Oncology Trial Under NMPA

A multinational oncology sponsor initiated a Phase III trial in 2020 using the NMPA’s silent approval system. The trial launched within 75 working days, compared to more than two years under the CFDA. This accelerated access demonstrated the impact of NMPA reforms on trial speed.

Case Study 2: CRO Adaptation to NMPA Oversight

A local CRO faced increased scrutiny during an NMPA inspection for data integrity. By implementing electronic data capture (EDC) systems and expanding staff training, the CRO achieved compliance and secured more multinational contracts, reflecting how reforms drive higher quality standards.

FAQs

1. Why was the CFDA replaced by the NMPA?

The transition aimed to modernize China’s regulatory system, centralize oversight, and align with international best practices.

2. How did the NMPA change trial approval timelines?

The NMPA introduced a 60-day silent approval system, reducing approval times from years to months, aligning with FDA and EMA benchmarks.

3. Are bridging studies still required in China?

Not always. If multinational data includes adequate Chinese patient representation, the NMPA may waive bridging studies.

4. How did ethics oversight improve under the NMPA?

The NMPA strengthened ethics committees and piloted centralized reviews, improving consistency compared to CFDA-era practices.

5. What impact did reforms have on CROs?

CROs faced higher compliance expectations but gained more opportunities as sponsors expanded trial activity in China.

6. Which therapeutic areas benefit most from NMPA reforms?

Oncology, rare diseases, and vaccines benefit most due to accelerated review pathways and greater data acceptance.

Conclusion & Call-to-Action

The transition from CFDA to NMPA fundamentally reshaped China’s clinical trial environment. By reducing timelines, improving ethics oversight, and expanding site accreditation, the reforms positioned China as a global leader in clinical research. For sponsors, these changes offer opportunities but demand strict compliance and proactive regulatory engagement. Organizations planning clinical trials in China should integrate NMPA strategies into global development plans, partner with experienced CROs, and invest in site capacity building to fully leverage China’s evolving regulatory landscape.

How China’s Clinical Trial Landscape Transformed from GCP 2003 to NMPA Reforms

Introduction

Clinical trials in China have undergone a dramatic transformation over the past two decades. From the initial implementation of Good Clinical Practice (GCP) standards in 2003 to the sweeping reforms of the National Medical Products Administration (NMPA) in the late 2010s, the regulatory environment has shifted toward global harmonization and efficiency. This evolution has been driven by China’s rapid emergence as both a major pharmaceutical market and a global hub for research and development. Sponsors, contract research organizations (CROs), and academic centers are now navigating an increasingly robust framework aligned with international guidelines, including the International Council for Harmonisation (ICH). These changes have created both opportunities and challenges: streamlined drug approvals, faster patient access to innovative therapies, and greater scrutiny in ethics, data integrity, and pharmacovigilance. Understanding this evolution is essential for global sponsors considering China in their clinical development strategy, as well as for domestic stakeholders seeking to compete in an internationalized research environment.

Background and Regulatory Framework

GCP 2003: Foundation of Modern Clinical Trials in China

China’s Ministry of Health issued the first GCP guidelines in 2003, marking the formal entry of China into internationally recognized clinical research. Modeled partly on ICH E6, the guidelines emphasized patient safety, informed consent, and data reliability. However, adoption was uneven, with many sites requiring significant training and infrastructure upgrades.

Transition from CFDA to NMPA

In 2018, the China Food and Drug Administration (CFDA) was restructured into the NMPA, signaling a broader commitment to regulatory modernization. The NMPA reforms introduced priority review channels, acceptance of foreign clinical data, and stricter site inspection protocols. These reforms brought China closer to regulatory practices seen in the U.S. FDA and European Medicines Agency (EMA).

Case Example: Oncology Drug Approvals

One of the most visible impacts of the NMPA reforms has been in oncology trials. Between 2015 and 2022, China saw a surge in first-in-class oncology drug approvals, many supported by multinational trials. This illustrates the effectiveness of expedited pathways and data harmonization policies.

Core Clinical Trial Insights

Approval Process and Timelines

Before reforms, clinical trial applications (CTAs) in China could take over two years for approval. Post-NMPA reforms, timelines have been reduced to as little as 60 working days under the “silent approval” system, where an absence of regulatory feedback within a specified timeframe signals tacit approval. This change has made China highly attractive for multinational clinical trials, particularly in oncology and rare diseases.

Patient Recruitment and Site Capacity

China’s large population provides an advantage for rapid patient recruitment. However, disparities between Tier-1 and Tier-2 hospitals remain a bottleneck. Tier-1 hospitals in major cities such as Beijing and Shanghai dominate trial participation due to their infrastructure and trained staff, while Tier-2 and Tier-3 hospitals often lack capacity. Sponsors increasingly collaborate with local CROs to expand trial reach.

Ethics Oversight and Informed Consent

Ethical review committees (IRBs) have proliferated since GCP 2003, but variability in review standards persists. The NMPA has sought to strengthen harmonization through centralized ethics review for multicenter trials. The challenge of ensuring genuine informed consent, especially in rural areas, remains a priority, with the use of eConsent emerging as a practical solution.

Data Integrity and Inspections

China has faced criticism in the past for data reliability issues. In 2015, a major data audit led to the withdrawal of over 80% of pending drug applications due to quality concerns. Since then, inspections have intensified, with the NMPA adopting risk-based GCP inspection models similar to FDA and EMA practices. Today, compliance with electronic data capture (EDC) systems and trial master file (TMF) standards is mandatory for sponsors.

Pharmacovigilance and Post-Market Commitments

The 2019 Drug Administration Law introduced stricter pharmacovigilance obligations. Sponsors must now establish safety monitoring systems, report adverse events promptly, and comply with post-market safety studies. These changes reflect China’s increasing alignment with ICH E2E and WHO pharmacovigilance frameworks.

Integration into Global Multiregional Clinical Trials (MRCTs)

China’s participation in ICH E17 guidelines for MRCTs has encouraged global sponsors to include Chinese sites earlier in development. Bridging studies, once mandatory, are now less common, provided that data from multinational cohorts include sufficient Chinese representation. This shift accelerates access to innovative therapies and reduces duplication of effort.

Best Practices & Preventive Measures

Sponsors conducting trials in China should prioritize early engagement with the NMPA through pre-submission consultations, ensure their protocols are adaptable to local hospital infrastructure, and partner with experienced CROs. Inspection readiness, training of investigators, and proactive CAPA systems are crucial for avoiding regulatory setbacks. Adopting harmonized SOPs across global and Chinese sites ensures consistency and reduces delays.

Scientific & Regulatory Evidence

The evolution of China’s regulatory framework draws directly from international standards. ICH E6 (R2) on GCP, EU Clinical Trials Regulation (EU CTR 536/2014), and WHO GCP have all influenced NMPA guidelines. Furthermore, China’s participation in ICH since 2017 has accelerated harmonization. These global references provide sponsors confidence that trials conducted in China will meet expectations for U.S. FDA and EMA submissions.

Special Considerations

China’s clinical trial environment also reflects unique considerations, including the integration of Traditional Chinese Medicine (TCM) into research, linguistic diversity impacting informed consent, and the growing role of digital health tools. Pediatric and rare disease trials are areas where China is actively creating tailored pathways, balancing scientific rigor with unmet medical needs.

When Sponsors Should Seek Regulatory Advice

Sponsors are advised to consult the NMPA during protocol design and prior to submission. Meetings equivalent to FDA’s Type B (pre-IND) and Type C consultations can clarify expectations and reduce review delays. Seeking advice is particularly important for first-in-human studies, adaptive trial designs, or submissions involving imported investigational products.

FAQs

1. When did China join the ICH?

China officially joined the International Council for Harmonisation (ICH) in June 2017, accelerating alignment with global trial standards.

2. How long does NMPA approval take compared to before reforms?

Prior to reforms, clinical trial applications could take 18–24 months. Today, reviews can be completed within 60 working days under the silent approval system.

3. Are bridging studies still required in China?

Bridging studies are no longer automatically required. If multinational data includes adequate Chinese representation, the NMPA may waive bridging requirements.

4. What are the main data integrity concerns in China?

Past audits revealed issues in recordkeeping and data fabrication. Reforms have since emphasized EDC systems, TMF compliance, and stringent inspections.

5. Can foreign sponsors conduct trials independently in China?

Yes, but partnerships with local CROs and accredited sites are essential for compliance and efficient execution.

6. What is the role of ethics committees in Chinese trials?

IRBs review study protocols, informed consent, and patient protections. The NMPA is working toward centralized ethics reviews for multicenter studies.

7. How does China regulate pharmacovigilance?

The 2019 Drug Administration Law mandates safety monitoring systems, expedited adverse event reporting, and post-market commitments, aligning with ICH E2E.

Conclusion & Call-to-Action

China’s journey from GCP 2003 to NMPA reforms demonstrates how quickly regulatory systems can modernize to meet global expectations. For sponsors, this evolution offers unprecedented opportunities but also demands strict compliance and cultural adaptability. Organizations considering China in their clinical development strategy should prioritize early regulatory engagement, invest in local partnerships, and adopt harmonized SOPs to succeed in this dynamic environment. Consulting with regulatory experts familiar with NMPA expectations will significantly increase the likelihood of trial success.